Cereto F, Molina I, González A, Del Valle O, Esteban R, Guardia J, Genescà J
Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Universitat Autónoma de Barcelona, Spain.
Aliment Pharmacol Ther. 2003 Mar 1;17(5):695-701. doi: 10.1046/j.1365-2036.2003.01491.x.
Norfloxacin decreases the incidence of spontaneous bacterial peritonitis in cirrhotics, but promotes the appearance of quinolone-resistant Escherichia coli.
: To define the characteristics of quinolone-resistant E. coli spontaneous bacterial peritonitis.
E. coli-positive ascitic fluid cultures were identified during a 6-year period. Data on quinolone-sensitive and quinolone-resistant E. coli spontaneous bacterial peritonitis were compared.
One hundred and two E. coli-positive ascitic fluid cultures were detected. Cirrhotics accounted for 67 cases. Spontaneous bacterial peritonitis was found in 47 of the 67 (70%) cases [35 (74%) caused by quinolone-sensitive and 12 (26%) caused by quinolone-resistant E. coli]. Norfloxacin prophylaxis was higher in the quinolone-resistant group (92% vs. 6%, P < 0.001). Compared with patients with quinolone-sensitive E. coli spontaneous bacterial peritonitis, those with quinolone-resistant E. coli spontaneous bacterial peritonitis showed a higher prevalence of associated immunosuppressive factors (immunosuppressive drugs, human immunodeficiency virus infection or cancer) (92% vs. 20%, P < 0.001). Steroid therapy was independently associated with quinolone-resistant E. coli spontaneous bacterial peritonitis (odds ratio, 49; 95% confidence interval, 3.4-699; P = 0.004). The Child-Pugh score (P = 0.03), immunosuppression (P = 0.02) and renal failure (P = 0.01) were independent predictors of E. coli spontaneous bacterial peritonitis-related mortality.
Associated immunosuppression is an important co-factor for the development of quinolone-resistant E. coli spontaneous bacterial peritonitis and for E. coli spontaneous bacterial peritonitis-related mortality.
诺氟沙星可降低肝硬化患者自发性细菌性腹膜炎的发生率,但会促使喹诺酮耐药性大肠埃希菌出现。
明确喹诺酮耐药性大肠埃希菌自发性细菌性腹膜炎的特征。
在6年期间对大肠埃希菌阳性腹水培养物进行鉴定。比较喹诺酮敏感和耐药大肠埃希菌自发性细菌性腹膜炎的数据。
共检测到102份大肠埃希菌阳性腹水培养物。肝硬化患者67例。67例患者中有47例(70%)发生自发性细菌性腹膜炎[35例(74%)由喹诺酮敏感大肠埃希菌引起,12例(26%)由喹诺酮耐药大肠埃希菌引起]。喹诺酮耐药组诺氟沙星预防性用药比例更高(92% 对6%,P<0.001)。与喹诺酮敏感大肠埃希菌自发性细菌性腹膜炎患者相比,喹诺酮耐药大肠埃希菌自发性细菌性腹膜炎患者合并免疫抑制因素(免疫抑制药物、人类免疫缺陷病毒感染或癌症)的患病率更高(92% 对20%,P<0.001)。类固醇治疗与喹诺酮耐药大肠埃希菌自发性细菌性腹膜炎独立相关(比值比,49;95%置信区间,3.4 - 699;P = 0.004)。Child-Pugh评分(P = 0.03)、免疫抑制(P = 0.02)和肾衰竭(P = 0.01)是大肠埃希菌自发性细菌性腹膜炎相关死亡率的独立预测因素。
合并免疫抑制是喹诺酮耐药大肠埃希菌自发性细菌性腹膜炎发生以及大肠埃希菌自发性细菌性腹膜炎相关死亡率的重要协同因素。